LEP and type 2 diabetes mellitus: Our results should inform future clinical trials that aim to reduce the burden of type 2 diabetes through the modification of serum levels of leptin and adiponectin and add (although non-experimentally) to the debate regarding the differential effects of leptin on type 2 diabetes (i.e., the ‘leptin resistance’ phenomenon present among diabetic obese individuals).